RU2672585C2 - Применение эрибулина и ленватиниба в качестве комбинированной терапии для лечения рака - Google Patents

Применение эрибулина и ленватиниба в качестве комбинированной терапии для лечения рака Download PDF

Info

Publication number: RU2672585C2
Authority: RU; Russia
Prior art keywords: cancer; pharmaceutically acceptable; acceptable salt; eribulin; lenvatinib
Prior art date: 2013-06-26

Application number

RU2016102158A

Other languages

English (en)

Russian (ru)

Other versions

RU2016102158A (ru

Inventor

Кенити НОМОТО

Цзяи У

Original Assignee

Эйсай Ар Энд Ди Менеджмент Ко., Лтд.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-06-26

Filing date

2014-06-26

Publication date

2018-11-16

2014-06-26 Application filed by Эйсай Ар Энд Ди Менеджмент Ко., Лтд. filed Critical Эйсай Ар Энд Ди Менеджмент Ко., Лтд.

2017-07-31 Publication of RU2016102158A publication Critical patent/RU2016102158A/ru

2018-11-16 Application granted granted Critical

2018-11-16 Publication of RU2672585C2 publication Critical patent/RU2672585C2/ru

Links

206010028980 Neoplasm Diseases 0.000 title claims abstract description 151
229960003649 eribulin Drugs 0.000 title claims abstract description 129
WOSKHXYHFSIKNG-UHFFFAOYSA-N lenvatinib Chemical compound C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 WOSKHXYHFSIKNG-UHFFFAOYSA-N 0.000 title claims abstract description 115
229960003784 lenvatinib Drugs 0.000 title claims abstract description 113
201000011510 cancer Diseases 0.000 title claims abstract description 92
238000011282 treatment Methods 0.000 title claims abstract description 47
UFNVPOGXISZXJD-XJPMSQCNSA-N eribulin Chemical compound C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 UFNVPOGXISZXJD-XJPMSQCNSA-N 0.000 title abstract 2
238000002648 combination therapy Methods 0.000 title description 3
150000003839 salts Chemical class 0.000 claims abstract description 137
238000000034 method Methods 0.000 claims abstract description 74
239000003814 drug Substances 0.000 claims abstract description 44
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 18
201000010099 disease Diseases 0.000 claims abstract description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 8
UFNVPOGXISZXJD-JBQZKEIOSA-N eribulin Chemical compound C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 UFNVPOGXISZXJD-JBQZKEIOSA-N 0.000 claims description 133
150000001875 compounds Chemical class 0.000 claims description 13
206010009944 Colon cancer Diseases 0.000 claims description 12
238000001990 intravenous administration Methods 0.000 claims description 12
201000001441 melanoma Diseases 0.000 claims description 12
206010027476 Metastases Diseases 0.000 claims description 8
206010006187 Breast cancer Diseases 0.000 claims description 7
208000026310 Breast neoplasm Diseases 0.000 claims description 7
208000001333 Colorectal Neoplasms Diseases 0.000 claims description 7
238000001802 infusion Methods 0.000 claims description 7
230000004614 tumor growth Effects 0.000 claims description 7
206010005949 Bone cancer Diseases 0.000 claims description 5
208000018084 Bone neoplasm Diseases 0.000 claims description 5
208000000453 Skin Neoplasms Diseases 0.000 claims description 5
208000029742 colonic neoplasm Diseases 0.000 claims description 5
201000005787 hematologic cancer Diseases 0.000 claims description 5
208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 5
230000028993 immune response Effects 0.000 claims description 5
230000009401 metastasis Effects 0.000 claims description 5
201000000849 skin cancer Diseases 0.000 claims description 5
208000024891 symptom Diseases 0.000 claims description 5
206010005003 Bladder cancer Diseases 0.000 claims description 4
208000003174 Brain Neoplasms Diseases 0.000 claims description 4
206010014733 Endometrial cancer Diseases 0.000 claims description 4
206010014759 Endometrial neoplasm Diseases 0.000 claims description 4
206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 4
208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
206010033128 Ovarian cancer Diseases 0.000 claims description 4
206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
206010060862 Prostate cancer Diseases 0.000 claims description 4
208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
206010038389 Renal cancer Diseases 0.000 claims description 4
208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
208000024770 Thyroid neoplasm Diseases 0.000 claims description 4
208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
206010017758 gastric cancer Diseases 0.000 claims description 4
201000010536 head and neck cancer Diseases 0.000 claims description 4
208000014829 head and neck neoplasm Diseases 0.000 claims description 4
230000008595 infiltration Effects 0.000 claims description 4
238000001764 infiltration Methods 0.000 claims description 4
201000010982 kidney cancer Diseases 0.000 claims description 4
HWLFIUUAYLEFCT-UHFFFAOYSA-N lenvatinib mesylate Chemical compound CS(O)(=O)=O.C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 HWLFIUUAYLEFCT-UHFFFAOYSA-N 0.000 claims description 4
208000032839 leukemia Diseases 0.000 claims description 4
201000007270 liver cancer Diseases 0.000 claims description 4
208000014018 liver neoplasm Diseases 0.000 claims description 4
201000005202 lung cancer Diseases 0.000 claims description 4
208000020816 lung neoplasm Diseases 0.000 claims description 4
230000001926 lymphatic effect Effects 0.000 claims description 4
208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
210000000056 organ Anatomy 0.000 claims description 4
201000008968 osteosarcoma Diseases 0.000 claims description 4
201000002528 pancreatic cancer Diseases 0.000 claims description 4
208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
230000002093 peripheral effect Effects 0.000 claims description 4
201000011549 stomach cancer Diseases 0.000 claims description 4
201000002510 thyroid cancer Diseases 0.000 claims description 4
201000005112 urinary bladder cancer Diseases 0.000 claims description 4
239000002552 dosage form Substances 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
230000002708 enhancing effect Effects 0.000 claims description 2
208000037819 metastatic cancer Diseases 0.000 claims description 2
208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 2
229960000439 eribulin mesylate Drugs 0.000 claims 2
229960001429 lenvatinib mesylate Drugs 0.000 claims 2
208000018420 bone fibrosarcoma Diseases 0.000 claims 1
230000000259 anti-tumor effect Effects 0.000 abstract description 15
239000000203 mixture Substances 0.000 abstract description 9
230000000694 effects Effects 0.000 abstract description 7
239000000126 substance Substances 0.000 abstract description 3
230000004663 cell proliferation Effects 0.000 abstract description 2
239000004615 ingredient Substances 0.000 abstract 1
229940079593 drug Drugs 0.000 description 39
210000004027 cell Anatomy 0.000 description 19
241000699670 Mus sp. Species 0.000 description 17
-1 6-carbamoyl-7-methoxyquinolin-4-yl Chemical group 0.000 description 15
230000037396 body weight Effects 0.000 description 14
239000003795 chemical substances by application Substances 0.000 description 14
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
241001465754 Metazoa Species 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 7
238000007619 statistical method Methods 0.000 description 6
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 5
FXNFULJVOQMBCW-VZBLNRDYSA-N halichondrin b Chemical compound O([C@@H]1[C@@H](C)[C@@H]2O[C@@H]3C[C@@]4(O[C@H]5[C@@H](C)C[C@@]6(C[C@@H]([C@@H]7O[C@@H](C[C@@H]7O6)[C@@H](O)C[C@@H](O)CO)C)O[C@H]5C4)O[C@@H]3C[C@@H]2O[C@H]1C[C@@H]1C(=C)[C@H](C)C[C@@H](O1)CC[C@H]1C(=C)C[C@@H](O1)CC1)C(=O)C[C@H](O2)CC[C@H]3[C@H]2[C@H](O2)[C@@H]4O[C@@H]5C[C@@]21O[C@@H]5[C@@H]4O3 FXNFULJVOQMBCW-VZBLNRDYSA-N 0.000 description 5
238000005259 measurement Methods 0.000 description 5
208000002154 non-small cell lung carcinoma Diseases 0.000 description 5
238000009097 single-agent therapy Methods 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 5
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical class OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
239000002246 antineoplastic agent Substances 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical class CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
201000008808 Fibrosarcoma Diseases 0.000 description 3
ZBLLGPUWGCOJNG-UHFFFAOYSA-N Halichondrin B Natural products CC1CC2(CC(C)C3OC4(CC5OC6C(CC5O4)OC7CC8OC9CCC%10OC(CC(C(C9)C8=C)C%11%12CC%13OC%14C(OC%15CCC(CC(=O)OC7C6C)OC%15C%14O%11)C%13O%12)CC%10=C)CC3O2)OC%16OC(CC1%16)C(O)CC(O)CO ZBLLGPUWGCOJNG-UHFFFAOYSA-N 0.000 description 3
238000000540 analysis of variance Methods 0.000 description 3
230000001093 anti-cancer Effects 0.000 description 3
238000013459 approach Methods 0.000 description 3
230000000973 chemotherapeutic effect Effects 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
239000003755 preservative agent Substances 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
238000002054 transplantation Methods 0.000 description 3
230000004580 weight loss Effects 0.000 description 3
GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical class OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
239000004322 Butylated hydroxytoluene Substances 0.000 description 2
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
102000004243 Tubulin Human genes 0.000 description 2
108090000704 Tubulin Proteins 0.000 description 2
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
238000011319 anticancer therapy Methods 0.000 description 2
235000010323 ascorbic acid Nutrition 0.000 description 2
229960005070 ascorbic acid Drugs 0.000 description 2
239000011668 ascorbic acid Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
229940095259 butylated hydroxytoluene Drugs 0.000 description 2
229940044683 chemotherapy drug Drugs 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
239000012091 fetal bovine serum Substances 0.000 description 2
229940126864 fibroblast growth factor Drugs 0.000 description 2
210000004907 gland Anatomy 0.000 description 2
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
238000002513 implantation Methods 0.000 description 2
238000011081 inoculation Methods 0.000 description 2
TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical class OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
238000002483 medication Methods 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
238000004264 monolayer culture Methods 0.000 description 2
238000001543 one-way ANOVA Methods 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
239000002504 physiological saline solution Substances 0.000 description 2
230000002335 preservative effect Effects 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
102000027426 receptor tyrosine kinases Human genes 0.000 description 2
108091008598 receptor tyrosine kinases Proteins 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical class OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
238000012360 testing method Methods 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
230000003442 weekly effect Effects 0.000 description 2
NAOLWIGVYRIGTP-UHFFFAOYSA-N 1,3,5-trihydroxyanthracene-9,10-dione Chemical class C1=CC(O)=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1 NAOLWIGVYRIGTP-UHFFFAOYSA-N 0.000 description 1
MQLACMBJVPINKE-UHFFFAOYSA-N 10-[(3-hydroxy-4-methoxyphenyl)methylidene]anthracen-9-one Chemical compound C1=C(O)C(OC)=CC=C1C=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MQLACMBJVPINKE-UHFFFAOYSA-N 0.000 description 1
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
KSUAHJQWRZFLQE-UHFFFAOYSA-N CS(=O)(=O)O.O1C=COC(C=CC=CC=CC=CC=CC=CC=CC=CC=CC=C1)=O Chemical compound CS(=O)(=O)O.O1C=COC(C=CC=CC=CC=CC=CC=CC=CC=CC=CC=C1)=O KSUAHJQWRZFLQE-UHFFFAOYSA-N 0.000 description 1
GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical class OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
238000001061 Dunnett's test Methods 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical class OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
241000353756 Halichondria okadai Species 0.000 description 1
206010019663 Hepatic failure Diseases 0.000 description 1
101001126417 Homo sapiens Platelet-derived growth factor receptor alpha Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical class OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
102000029749 Microtubule Human genes 0.000 description 1
108091022875 Microtubule Proteins 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
229940123237 Taxane Drugs 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
241000021375 Xenogenes Species 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
229940024606 amino acid Drugs 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
229940009444 amphotericin Drugs 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
229940045799 anthracyclines and related substance Drugs 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002111 antiemetic agent Substances 0.000 description 1
229940125683 antiemetic agent Drugs 0.000 description 1
239000002257 antimetastatic agent Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
150000008107 benzenesulfonic acids Chemical class 0.000 description 1
150000001558 benzoic acid derivatives Chemical class 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000000872 buffer Substances 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical class O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
230000007012 clinical effect Effects 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
229940109239 creatinine Drugs 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
230000001934 delay Effects 0.000 description 1
238000002716 delivery method Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
238000013401 experimental design Methods 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
230000012010 growth Effects 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
229940118951 halaven Drugs 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical class I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
229920001477 hydrophilic polymer Polymers 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000007788 liquid Substances 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
208000007903 liver failure Diseases 0.000 description 1
231100000835 liver failure Toxicity 0.000 description 1
150000002678 macrocyclic compounds Chemical class 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
108010082117 matrigel Proteins 0.000 description 1
231100000682 maximum tolerated dose Toxicity 0.000 description 1
239000002609 medium Substances 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
210000004688 microtubule Anatomy 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
238000011580 nude mouse model Methods 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical class C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
229940055726 pantothenic acid Drugs 0.000 description 1
235000019161 pantothenic acid Nutrition 0.000 description 1
239000011713 pantothenic acid Substances 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
150000003016 phosphoric acids Chemical class 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
235000018102 proteins Nutrition 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
230000005855 radiation Effects 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
208000000649 small cell carcinoma Diseases 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
230000003068 static effect Effects 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
150000005846 sugar alcohols Chemical class 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
230000005747 tumor angiogenesis Effects 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
238000007492 two-way ANOVA Methods 0.000 description 1
230000036269 ulceration Effects 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
229960003048 vinblastine Drugs 0.000 description 1
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Oncology (AREA)
Hematology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Dermatology (AREA)

RU2016102158A 2013-06-26 2014-06-26 Применение эрибулина и ленватиниба в качестве комбинированной терапии для лечения рака RU2672585C2 (ru)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201361839542P	2013-06-26	2013-06-26
US61/839,542		2013-06-26
PCT/JP2014/067723 WO2014208774A1 (en)	2013-06-26	2014-06-26	Use of eribulin and lenvatinib as combination therapy for treatment of cancer

Publications (2)

Publication Number	Publication Date
RU2016102158A RU2016102158A (ru)	2017-07-31
RU2672585C2 true RU2672585C2 (ru)	2018-11-16

Family

ID=51210708

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
RU2016102158A RU2672585C2 (ru)	2013-06-26	2014-06-26	Применение эрибулина и ленватиниба в качестве комбинированной терапии для лечения рака

Country Status (12)

Country	Link
US (1)	US9549922B2 (2)
EP (1)	EP3013335B1 (2)
JP (1)	JP6404242B2 (2)
KR (1)	KR102265952B1 (2)
CN (1)	CN105338977B (2)
AU (1)	AU2014299699B2 (2)
BR (1)	BR112015029386B1 (2)
CA (1)	CA2915005C (2)
ES (1)	ES2705698T3 (2)
IL (1)	IL242386B (2)
RU (1)	RU2672585C2 (2)
WO (1)	WO2014208774A1 (2)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN102369008B (zh)	2009-03-30	2014-10-29	卫材R&D管理有限公司	脂质体组合物
MY162940A (en)	2009-08-19	2017-07-31	Eisai R&D Man Co Ltd	Quinoline derivative-containing pharmaceutical composition
JP6038128B2 (ja)	2011-06-03	2016-12-07	エーザイ・アール・アンド・ディー・マネジメント株式会社	レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
PT3524595T (pt)	2014-08-28	2022-09-19	Eisai R&D Man Co Ltd	Derivado de quinolina altamente puro e método para produção do mesmo
LT3263106T (lt)	2015-02-25	2024-01-10	Eisai R&D Management Co., Ltd.	Chinolino darinių kartumo sumažinimo būdas
KR102662228B1 (ko)	2015-03-04	2024-05-02	머크 샤프 앤드 돔 코포레이션	암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
AU2016226157B2 (en) *	2015-03-04	2022-01-27	Eisai R&D Management Co., Ltd.	Combination of a PD-1 antagonist and eribulin for treating cancer
MX373231B (es)	2015-06-16	2020-05-08	Eisai R&D Man Co Ltd	Agente anticancerigeno.
US12220398B2 (en)	2015-08-20	2025-02-11	Eisai R&D Management Co., Ltd.	Tumor therapeutic agent
WO2017188350A1 (ja) *	2016-04-28	2017-11-02	エーザイ・アール・アンド・ディー・マネジメント株式会社	腫瘍の成長を抑制する方法
CN105832732A (zh) *	2016-05-30	2016-08-10	青岛云天生物技术有限公司	一种用于胃癌治疗的药物组合物及其应用
US10865212B2 (en)	2017-01-02	2020-12-15	Yonsung Fine Chemical Co.. Ltd.	Intermediate for preparing eribulin mesylate and process for preparing the same
US12303505B2 (en) *	2017-02-08	2025-05-20	Eisai R&D Management Co., Ltd.	Tumor-treating pharmaceutical composition
RU2019134940A (ru)	2017-05-16	2021-06-16	Эйсай Ар Энд Ди Менеджмент Ко., Лтд.	Лечение гепатоцеллюлярной карциномы
WO2019097073A1 (en)	2017-11-20	2019-05-23	Basilea Pharmaceutica International AG	Pharmaceutical combinations for use in the treatment of neoplastic diseases
CN107973804B (zh) *	2017-11-29	2020-07-03	戊言医药科技（上海）有限公司	艾瑞布林中间体的合成方法
MA51570A (fr) *	2018-01-10	2020-11-18	Eisai R&D Man Co Ltd	Polythérapies pour le traitement du carcinome hépatocellulaire
CN109793736A (zh) *	2019-01-31	2019-05-24	徐州医科大学	一种乐伐替尼在制备自然杀伤细胞激动剂中的应用
US12036204B2 (en)	2019-07-26	2024-07-16	Eisai R&D Management Co., Ltd.	Pharmaceutical composition for treating tumor
US11083705B2 (en)	2019-07-26	2021-08-10	Eisai R&D Management Co., Ltd.	Pharmaceutical composition for treating tumor
CN114028394A (zh) *	2021-05-21	2022-02-11	中山大学	低剂量仑伐替尼在制备治疗肝癌的药物中的用途
US20250064794A1 (en) *	2021-08-10	2025-02-27	Eisai R&D Management Co., Ltd.	A therapeutic combination comprising a tigit antagonist, a pd-1 antagonist, and lenvatinib

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2012119077A1 (en) *	2011-03-02	2012-09-07	Morphotek Inc.	Co -administration of eribulin and farletuzumab for the treatment of breast cancer
WO2012166899A2 (en) *	2011-06-03	2012-12-06	Eisai R&D Management Co., Ltd.	Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6653341B1 (en)	1998-06-17	2003-11-25	Eisai Co., Ltd.	Methods and compositions for use in treating cancer
JP4454151B2 (ja)	1998-06-17	2010-04-21	エーザイ・アール・アンド・ディー・マネジメント株式会社	大環状類似体及びそれらの使用並びに調製方法
US8097648B2 (en)	1998-06-17	2012-01-17	Eisai R&D Management Co., Ltd.	Methods and compositions for use in treating cancer
AU9598601A (en)	2000-10-20	2002-04-29	Eisai Co Ltd	Nitrogenous aromatic ring compounds
JP4542783B2 (ja)	2002-03-05	2010-09-15	エーザイ・アール・アンド・ディー・マネジメント株式会社	スルホンアミド含有複素環化合物及び血管新生抑制剤とを組み合わせてなる抗腫瘍剤
US7683172B2 (en)	2003-11-11	2010-03-23	Eisai R&D Management Co., Ltd.	Urea derivative and process for preparing the same
KR100804566B1 (ko)	2003-12-25	2008-02-20	에자이 알앤드디 매니지먼트 가부시키가이샤	4-(3-클로로-4-(시클로프로필아미노카르보닐)아미노페녹시)-7-메톡시-6-퀴놀린카르복사미드의 염 또는 그 용매화물의 결정 및 이들의 제조 방법
SI2522663T1 (sl) *	2004-06-03	2015-08-31	Eisai R&D Management Co., Ltd.	Vmesne spojine za pripravo halihondrina B
US8772269B2 (en)	2004-09-13	2014-07-08	Eisai R&D Management Co., Ltd.	Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
JP4989476B2 (ja)	2005-08-02	2012-08-01	エーザイ・アール・アンド・ディー・マネジメント株式会社	血管新生阻害物質の効果を検定する方法
AU2006309551B2 (en)	2005-11-07	2012-04-19	Eisai R & D Management Co., Ltd.	Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
CN104706637A (zh)	2006-05-18	2015-06-17	卫材R&D管理有限公司	针对甲状腺癌的抗肿瘤剂
JPWO2008088088A1 (ja)	2007-01-19	2010-05-13	エーザイ・アール・アンド・ディー・マネジメント株式会社	膵癌治療用組成物
CA2676796C (en)	2007-01-29	2016-02-23	Eisai R & D Management Co., Ltd.	Composition for treatment of undifferentiated gastric cancer
KR101667960B1 (ko) *	2007-07-25	2016-10-20	에자이 알앤드디 매니지먼트 가부시키가이샤	암 치료에서 이용하기 위한 멀티키나아제 억제제
BRPI0817909B1 (pt)	2007-10-03	2022-06-21	Eisai R&D Management Co., Ltd	Métodos de obtenção e de preparação de uma composição diastereomericamente pura, compostos, e método para produzir os referidos compostos
US8952035B2 (en)	2007-11-09	2015-02-10	Eisai R&D Management Co., Ltd.	Combination of anti-angiogenic substance and anti-tumor platinum complex
KR101506062B1 (ko)	2008-01-29	2015-03-25	에자이 알앤드디 매니지먼트 가부시키가이샤	혈관 저해 물질과 탁산의 병용
RU2579511C2 (ru)	2010-01-26	2016-04-10	Эйсай Ар Энд Ди Менеджмент Ко., Лтд.	Производные фуро[3,2-в]пирана, применимые в синтезе аналогов
CN102958523B (zh)	2010-06-25	2014-11-19	卫材R&D管理有限公司	使用具有激酶抑制作用的组合的抗肿瘤剂
US20120077837A1 (en)	2010-09-24	2012-03-29	Eisai R&D Management Co., Ltd.	Anti-tumor agent
EP2686441B1 (en) *	2011-03-18	2019-05-08	Eisai R&D Management Co., Ltd.	Methods and uses for predicting response to eribulin
CN103402519B (zh) *	2011-04-18	2015-11-25	卫材R&D管理有限公司	肿瘤治疗剂
WO2012154935A1 (en)	2011-05-12	2012-11-15	Eisai R&D Management Co., Ltd.	Biomarkers that are predictive of responsiveness or non-responsiveness to treatment with lenvatinib or a pharmaceutically acceptable salt thereof
CA2940983A1 (en)	2014-03-03	2015-09-11	Eisai R&D Management Co., Ltd.	Use of eribulin and mtor inhibitors as combination therapy for the treatment of cancer
WO2015184145A1 (en)	2014-05-28	2015-12-03	Eisai R&D Management Co., Ltd.	Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer
US20170100367A1 (en)	2014-05-28	2017-04-13	Eisai R&D Management Co., Ltd.	Use of eribulin in the treatment of cancer
JP6644479B2 (ja)	2014-06-24	2020-02-12	エーザイ・アール・アンド・ディー・マネジメント株式会社	がん治療のための併用療法としてのエリブリンとｓ−１（もしくは５−ｆｕ）の使用

2014
- 2014-06-26 BR BR112015029386-7A patent/BR112015029386B1/pt active IP Right Grant
- 2014-06-26 AU AU2014299699A patent/AU2014299699B2/en active Active
- 2014-06-26 RU RU2016102158A patent/RU2672585C2/ru active
- 2014-06-26 KR KR1020167001713A patent/KR102265952B1/ko active Active
- 2014-06-26 CA CA2915005A patent/CA2915005C/en active Active
- 2014-06-26 WO PCT/JP2014/067723 patent/WO2014208774A1/en not_active Ceased
- 2014-06-26 ES ES14739971T patent/ES2705698T3/es active Active
- 2014-06-26 US US14/315,930 patent/US9549922B2/en active Active
- 2014-06-26 JP JP2015562231A patent/JP6404242B2/ja active Active
- 2014-06-26 EP EP14739971.1A patent/EP3013335B1/en active Active
- 2014-06-26 CN CN201480036218.0A patent/CN105338977B/zh active Active
2015
- 2015-11-01 IL IL242386A patent/IL242386B/en active IP Right Grant

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2012119077A1 (en) *	2011-03-02	2012-09-07	Morphotek Inc.	Co -administration of eribulin and farletuzumab for the treatment of breast cancer
WO2012166899A2 (en) *	2011-06-03	2012-12-06	Eisai R&D Management Co., Ltd.	Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Харкевич Д.А. Фармакология / Учебник, 2010, 10-е издание, стр.72-82. Микуляк Н.И. и др. Изучение противоопухолевого и антиметастатического эффектов противоопухолевых антибиотиков при раздельном и совместном применении с мексидолом / Известия ВУЗов. Поволжский регион. Медицинские науки. 2007. Хирургическая онкология / surgery.su, 2009, URL: http://oncosurgery.surgery.su/. *

Also Published As

Publication number	Publication date
JP2016528162A (ja)	2016-09-15
US9549922B2 (en)	2017-01-24
CA2915005C (en)	2021-12-28
AU2014299699A1 (en)	2015-12-10
JP6404242B2 (ja)	2018-10-10
EP3013335A1 (en)	2016-05-04
KR20160023816A (ko)	2016-03-03
EP3013335B1 (en)	2018-11-07
CA2915005A1 (en)	2014-12-31
WO2014208774A1 (en)	2014-12-31
RU2016102158A (ru)	2017-07-31
BR112015029386A8 (pt)	2020-03-17
US20150005343A1 (en)	2015-01-01
ES2705698T3 (es)	2019-03-26
IL242386B (en)	2019-06-30
BR112015029386A2 (pt)	2017-07-25
BR112015029386B1 (pt)	2023-11-14
AU2014299699B2 (en)	2019-10-10
CN105338977A (zh)	2016-02-17
KR102265952B1 (ko)	2021-06-16
CN105338977B (zh)	2018-10-16

Publication	Publication Date	Title
RU2672585C2 (ru)	2018-11-16	Применение эрибулина и ленватиниба в качестве комбинированной терапии для лечения рака
ES2248070T3 (es)	2006-03-16	Decetaxel en combinacioncon rhumab hr2 para el tratamiento de canceres.
US10238630B2 (en)	2019-03-26	Use of eribulin and poly (ADP ribose) polymerase (PARP) inhibitors as combination therapy for the treatment of cancer
ES2902665T3 (es)	2022-03-29	Tratamiento del cáncer con combinación de plinabulina y taxano
JP7169297B2 (ja)	2022-11-10	再発膠芽腫（ｒｇｂｍ）の治療方法
ES2970224T3 (es)	2024-05-27	Tinostamustina para su uso en el tratamiento del sarcoma
US20140066383A1 (en)	2014-03-06	Methods of treating cancer
JP2019505585A (ja)	2019-02-28	２−ブロモ−１−（３，３−ジニトロアゼチジン−１−イル）エタノンの静脈内投与のための組成物および方法
US20170100367A1 (en)	2017-04-13	Use of eribulin in the treatment of cancer
JP2019516709A (ja)	2019-06-20	癌の処置におけるジヒドロテストステロンならびにジヒドロテストステロン誘導体および促進剤
JP4672257B2 (ja)	2011-04-20	エポチロンを含む組成物およびカルチノイド症候群の治療のためのそれらの使用
JP6370801B2 (ja)	2018-08-08	肝疾患または肝障害の治療のための使用および方法
US20190046513A1 (en)	2019-02-14	Combination therapies of hdac inhibitors and tubulin inhibitors
US20120251628A1 (en)	2012-10-04	Compositions and methods for treatment of cancer
IL294399A (en)	2022-08-01	Combination therapy for treating cancer
RU2428188C2 (ru)	2011-09-10	Комбинация, содержащая n-(3-метокси-5-метилпиразин-2-ил)-2-(4-[1,3,4-оксадиазол-2-ил]фенил)пиридин-3-сульфонамид и антимитотическое средство, для лечения злокачественного новообразования
JP6644479B2 (ja)	2020-02-12	がん治療のための併用療法としてのエリブリンとｓ−１（もしくは５−ｆｕ）の使用
JP2014231518A (ja)	2014-12-11	子宮腫瘍の治療用医薬の調製のための７−ｔ−ブトキシイミノメチルカンプトテシンの使用
EP4640218A1 (en)	2025-10-29	Use of sultam compound in treating biliary tract cancer
WO2024246824A1 (en)	2024-12-05	Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer
JP2015509929A (ja)	2015-04-02	カバジタキセルの新規な小児への使用
TW201032798A (en)	2010-09-16	Antitumor combination combining AVE8062 and docetaxel
JP2010507628A (ja)	2010-03-11	骨ガンの処置又は予防のためのｍｔｋｉ１の使用